Trevi Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TREVI THERAPEUTICS, INC. | ||
| Date: March 20, 2024 | By: | /s/ Jennifer Good |
|---|---|---|
| Jennifer Good | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Jennifer Good | President and Chief Executive Officer, Director | March 20, 2024 |
| Jennifer Good | (Principal Executive Officer) | |
| /s/ Lisa Delfini | Chief Financial Officer | March 20, 2024 |
| Lisa Delfini | (Principal Financial Officer) | |
| /s/ Christopher Galletta | Controller | March 20, 2024 |
| Christopher Galletta | (Principal Accounting Officer) | |
| /s/ David Meeker, M.D. | Chairman of the Board | March 20, 2024 |
| David Meeker, M.D. | ||
| /s/ James V. Cassella, Ph.D. | Director | March 20, 2024 |
| James V. Cassella, Ph.D. /s/ Dominick Colangelo | Director | March 20, 2024 |
| Dominick Colangelo | ||
| /s/ Michael Heffernan | Director | March 20, 2024 |
| Michael Heffernan | ||
| /s/ Edward Mathers | Director | March 20, 2024 |
| Edward Mathers | ||
| /s/ Anne VanLent | Director | March 20, 2024 |
| Anne VanLent | ||
Index to Consolidated Financial Statements
Years Ended December 31, 2023 and 2022
Contents
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Financial Statements | |
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Comprehensive Loss | F-4 |
| Consolidated Statements of Stockholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.